Standard Biotools (LAB) Long-Term Debt Issuances (2011 - 2022)
Standard Biotools (LAB) reported Long-Term Debt Issuances of $25.0 million for Q1 2022, up 150.0% on a QoQ basis from $10.0 million in Q3 2021.
Standard Biotools (LAB) has 4 years of Long-Term Debt Issuances data on file, last reported at $25.0 million in Q1 2022.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $25.0 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $25.0 million (changed N/A YoY) and the FY2022 annual result came in at $25.0 million, up 265.6% from the prior year.
- Long-Term Debt Issuances climbed to $25.0 million in Q1 2022 per LAB's latest filing, from $10.0 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $25.0 million in Q1 2022 and bottomed at $10.0 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 19.86 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 11.71 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 1.15 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Standard Biotools | 448.37 Mn | -6.80 Mn | 11.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 25.00 Mn |
| Mar 31, 2022 | 25.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Dec 31, 2014 | 1,000.00 |
| Dec 31, 2014 | 1,000.00 |
| Mar 31, 2014 | 195.21 Mn |
| Mar 31, 2014 | 195.21 Mn |
| Mar 31, 2011 | 5.00 Mn |
| Mar 31, 2011 | 5.00 Mn |